Nautilus Biotechnology (NASDAQ:NAUT) Now Covered by Guggenheim

Analysts at Guggenheim started coverage on shares of Nautilus Biotechnology (NASDAQ:NAUT) in a note issued to investors on Thursday, MarketBeat reports. The brokerage set a “buy” rating and a $6.00 price target on the stock. Guggenheim’s price target points to a potential upside of 156.41% from the stock’s current price.

Separately, Jefferies Financial Group started coverage on Nautilus Biotechnology in a report on Monday, June 3rd. They issued a “hold” rating and a $3.00 target price on the stock.

Nautilus Biotechnology Trading Up 2.6 %

Shares of NASDAQ NAUT opened at $2.34 on Thursday. Nautilus Biotechnology has a twelve month low of $2.19 and a twelve month high of $4.00. The stock has a 50 day moving average of $2.61 and a two-hundred day moving average of $2.77. The stock has a market cap of $293.12 million, a P/E ratio of -4.25 and a beta of 1.25.

Nautilus Biotechnology (NASDAQ:NAUT) last released its earnings results on Tuesday, April 30th. The company reported ($0.15) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.16) by $0.01. As a group, research analysts predict that Nautilus Biotechnology will post -0.68 earnings per share for the current year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of NAUT. Price T Rowe Associates Inc. MD grew its holdings in Nautilus Biotechnology by 35.8% in the first quarter. Price T Rowe Associates Inc. MD now owns 16,078 shares of the company’s stock valued at $48,000 after purchasing an additional 4,239 shares during the last quarter. Vanguard Group Inc. grew its holdings in Nautilus Biotechnology by 1.0% in the first quarter. Vanguard Group Inc. now owns 2,859,402 shares of the company’s stock valued at $8,407,000 after purchasing an additional 29,604 shares during the last quarter. China Universal Asset Management Co. Ltd. grew its holdings in Nautilus Biotechnology by 66.6% in the first quarter. China Universal Asset Management Co. Ltd. now owns 24,076 shares of the company’s stock valued at $71,000 after purchasing an additional 9,624 shares during the last quarter. Perceptive Advisors LLC grew its holdings in Nautilus Biotechnology by 38.2% in the fourth quarter. Perceptive Advisors LLC now owns 12,594,211 shares of the company’s stock valued at $37,657,000 after purchasing an additional 3,483,060 shares during the last quarter. Finally, Axxcess Wealth Management LLC acquired a new stake in Nautilus Biotechnology in the fourth quarter valued at $30,000. Institutional investors and hedge funds own 50.71% of the company’s stock.

Nautilus Biotechnology Company Profile

Nautilus Biotechnology, Inc, a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. The company develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumables, and software analysis.